Article Contents ::
- 1 The Brand Name FAXINE Has Generic Salt :: Venlafaxine
- 2 FAXINE Is From Company Theo Ph. Priced :: Rs. N.I.
- 3 FAXINE have Venlafaxine is comes under Sub class Anxiolytics of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Anxiolytics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name FAXINE Has Generic Salt :: Venlafaxine
FAXINE Is From Company Theo Ph. Priced :: Rs. N.I.
FAXINE have Venlafaxine is comes under Sub class Anxiolytics of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anxiolytics
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Venlafaxine | XR TAB | Rs. N.I. | 10/10/2010 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10/10/2010 |
| FAXINE | Theo Ph. | 37.5/75/150;MG | 10/10/2010 | Rs. N.I. |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Theo Ph. :: FAXINE | Venlafaxine | Nervous System | Anxiolytics |
Indications for Drugs ::
Depression, Anxiety, Panic disorder, Social anxiety disorder
Drug Dose ::
Adult: PO Depression Initial: 75 mg/day in 2-3 divided doses, increase slowly if needed. Max: 375 mg/day. Anxiety; Social anxiety disorder Extended release Initial: 75 mg once daily, may increase slowly if needed. Max: 225 mg/day. Panic disorder 37.5 mg once daily for 1st 7 days, may increase slowly if needed. Max: 225 mg/day. Hepatic impairment: Mild to moderate: Reduce dose by 50%.
Contraindication ::
<18 yr. Lactation. Uncontrolled hypertension; high risk of serious ventricular arrhythmia. Drug Precautions ::
Moderate to severe renal or hepatic impairment. Conditions which may be worsened by increase in heart rate. History of MI, bleeding disorder, epilepsy, hypomania or mania. Raised Intraocular pressure or risk at angle-closure glaucoma. May impair performance of skilled tasks, driving or machinery operation. Monitor BP and serum cholesterol regularly. Monitor closely during early therapy until depression improves due to increased risk of suicide. Avoid abrupt withdrawal. Withdraw gradually over at least 1-2 wk and monitor for withdrawal symptoms e.g. fatigue, headache, nausea, vomiting, palpitations. Discontinue if seizure develops or increase in seizure frequency. Elderly, pregnancy.
Drug Side Effects ::
Nausea, vomiting, anorexia, dry mouth, constipation, orthostatic hypotension, tremour, sweating, rash, anxiety, dizziness, fatigue, headache, syncope, insomnia, somnolence, constipation, hyponatraemia, sexual dysfunction, dyspepsia, visual disturbances, mydriasis, increased cholesterol concentrations, increased LFT. Aggressive behaviour (especially at the start and when stoppping therapy). Potentially Fatal: Blood dyscrasias, Stevens-Johnson syndrome, hepatitis.
Pregnancy category ::
3
Drug Mode of Action ::
Venlafaxine and its active metabolite O-desmethylvenlafaxine selectively inhibit the neuronal reuptake of serotonin, norepinephrine and to a lesser extent dopamine. It has minimal affinity for muscarinic, histamine, or ?1-adrenergic receptors. It appears to be as effective as standard antidepressants but w/ a lower incidence of anticholinergic, sedative and CV side effects.
Drug Interactions ::
Increased risk of serotonin syndrome w/ TCA, SSRI, SNRI, lithium, sibutramine, tramadol. May increase serum levels w/ CYP3A4 inhibitors (e.g. ketoconazole, atazanavir, clarithromycin). May increase serum levels of haloperidol. May decrease serum levels of indinavir. May increase bleeding risk w/ aspirin, NSAIDs, warfarin and other anticoagulants. Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
